News from Eli Lilly and Company Limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Feb 15, 2017, 17:56 ET Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today additional detailed results from RA-BEAM – a pivotal phase...


Feb 09, 2017, 13:00 ET Lilly To Present At Leerink Partners Global Healthcare Conference

Eli Lilly and Company (NYSE: LLY) will present at the Leerink Partners Global Healthcare Conference on Thursday, February 16, 2017. Enrique...


Feb 09, 2017, 06:45 ET Carolyn R. Bertozzi, Ph.D., Elected to Lilly Board of Directors

The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Carolyn R. Bertozzi, Ph.D., as a new member, effective Feb. 10, 2017. As a...


Feb 08, 2017, 16:00 ET Lilly to Present at Cowen Health Care Conference

Eli Lilly and Company (NYSE: LLY) will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017. David A....


Feb 08, 2017, 06:45 ET Lilly's Trulicity® (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes

The label for Eli Lilly and Company's (NYSE: LLY) once-weekly Trulicity® (dulaglutide) is now updated to include use in combination with basal...


Feb 02, 2017, 09:00 ET Japan IP High Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents

Eli Lilly and Company (NYSE: LLY) today announced that the Japan IP High Court confirmed the decisions of the Japan Patent Office and ruled in...


Jan 31, 2017, 06:25 ET Lilly Reports Fourth-Quarter and Full-Year 2016 Results

Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2016....


Jan 30, 2017, 12:00 ET Lilly Revises Time for Conference Call for Fourth-Quarter 2016 Financial Results Announcement

Eli Lilly and Company (NYSE: LLY) will host a call for investors, media and the general public at 11:30 a.m. Eastern Time on January 31, 2017 to...


Jan 18, 2017, 06:45 ET Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid

Eli Lilly and Company (NYSE: LLY) and CoLucid Pharmaceuticals, Inc. (NASD: CLCD) today announced an agreement for Lilly to acquire CoLucid for...


Jan 13, 2017, 16:51 ET U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has...


Jan 12, 2017, 11:05 ET U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the district court's decision...


Jan 11, 2017, 06:45 ET Lilly and Merck Expand Immuno-Oncology Collaboration

Eli Lilly and Company (NYSE: LLY) today announced the expansion of an existing immuno-oncology collaboration with Merck, known as MSD outside the...


Jan 05, 2017, 16:45 ET Lilly Confirms Date and Conference Call for Fourth-Quarter 2016 Financial Results Announcement

Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2016 financial results on Tuesday, January 31, 2017. Lilly will...


Jan 05, 2017, 06:59 ET Lilly to Adjust Organization and Leadership Structure to Better Align with Growth Opportunities

Eli Lilly and Company (NYSE: LLY) today announced a series of changes to its organization and leadership structure to better align them...


Jan 03, 2017, 09:45 ET Lilly to Present at J.P. Morgan Healthcare Conference

Eli Lilly and Company (NYSE: LLY) will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017. David A. Ricks,...


Dec 16, 2016, 14:06 ET Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) Tablets in Updated American Diabetes Association's 2017 Standards

The American Diabetes Association's (ADA) 2017 Standards of Medical Care in Diabetes specifically include a new recommendation to consider the use...


Dec 16, 2016, 07:48 ET CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA)

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the European Medicines Agency's (EMA) Committee for...


Dec 15, 2016, 06:25 ET Lilly Provides 2017 Financial Guidance and 2016 Update, Reaffirms Financial Expectations Through the Remainder of the Decade

Eli Lilly and Company (NYSE: LLY) today announced its 2017 financial guidance and highlighted key events for the upcoming year. The company...


Dec 13, 2016, 06:30 ET Lilly Announces Program to Provide Insulin at Discounted Prices

Eli Lilly and Company (NYSE: LLY) today announced that people who use Lilly insulin will be able to access discounted prices for their purchases...


Dec 12, 2016, 18:00 ET Lilly Announces Dividend Increase

The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 2 percent increase in its quarterly dividend. The dividend for the...


Dec 12, 2016, 15:28 ET U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes

The U.S. Food and Drug Administration (FDA) has approved Synjardy® XR (empagliflozin and metformin hydrochloride extended-release) tablets for...


Dec 09, 2016, 07:00 ET Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease

Eli Lilly and Company (NYSE: LLY) and AstraZeneca announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42...


Dec 08, 2016, 21:15 ET Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at the Clinical Trials on Alzheimer's Disease (CTAD) 2016 Meeting

Eli Lilly and Company (NYSE:LLY) today presented detailed results of its phase 3 EXPEDITION3 trial at the 9th Clinical Trials on Alzheimer's...


Dec 08, 2016, 08:30 ET Lilly Presents neoMONARCH Phase 2 Data on Abemaciclib in Early-Stage Breast Cancer

Eli Lilly and Company (NYSE: LLY) today announced that the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor,...